Abzena PLC (LON:ABZA)‘s stock had its “buy” rating reiterated by equities research analysts at Numis Securities Ltd in a report released on Thursday. They presently have a GBX 80 ($1.03) target price on the stock. Numis Securities Ltd’s price target indicates a potential upside of 135.29% from the stock’s previous close.

Separately, FinnCap restated a “buy” rating and issued a GBX 80 ($1.03) target price on shares of Abzena PLC in a research note on Wednesday, August 30th.

Abzena PLC (LON:ABZA) remained flat at GBX 34.00 during mid-day trading on Thursday. 10,950 shares of the company’s stock were exchanged. The firm has a 50 day moving average of GBX 45.41 and a 200-day moving average of GBX 41.25. Abzena PLC has a one year low of GBX 31.00 and a one year high of GBX 66.00. The stock’s market capitalization is GBX 46.87 million.

WARNING: “Abzena PLC’s (ABZA) Buy Rating Reaffirmed at Numis Securities Ltd” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/09/16/abzena-plcs-abza-buy-rating-reaffirmed-at-numis-securities-ltd.html.

About Abzena PLC

Abzena plc is a life sciences company. The Company provides technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It has a global customer base which includes approximately 20 biopharmaceutical companies, as well as large and small biotech companies and academic groups.

Receive News & Ratings for Abzena PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abzena PLC and related companies with MarketBeat.com's FREE daily email newsletter.